202 related articles for article (PubMed ID: 30553523)
41. Latent Warheads for Targeted Cancer Therapy: Design and Synthesis of pro-Pyrrolobenzodiazepines and Conjugates.
Vlahov IR; Qi L; Kleindl PJ; Santhapuram HK; Felten A; Parham GL; Wang K; You F; Vaughn JF; Hahn SJ; Klein HF; Vetzel M; Reddy JA; Nelson M; Nicoson J; Leamon CP
Bioconjug Chem; 2017 Dec; 28(12):2921-2931. PubMed ID: 29211454
[TBL] [Abstract][Full Text] [Related]
42. Antibody drug conjugates.
Bakhtiar R
Biotechnol Lett; 2016 Oct; 38(10):1655-64. PubMed ID: 27334710
[TBL] [Abstract][Full Text] [Related]
43. Dithiocarbamate/piperazine bridged pyrrolobenzodiazepines as DNA-minor groove binders: synthesis, DNA-binding affinity and cytotoxic activity.
Kamal A; Sreekanth K; Shankaraiah N; Sathish M; Nekkanti S; Srinivasulu V
Bioorg Chem; 2015 Apr; 59():23-30. PubMed ID: 25665519
[TBL] [Abstract][Full Text] [Related]
44. Natural Product Splicing Inhibitors: A New Class of Antibody-Drug Conjugate (ADC) Payloads.
Puthenveetil S; Loganzo F; He H; Dirico K; Green M; Teske J; Musto S; Clark T; Rago B; Koehn F; Veneziale R; Falahaptisheh H; Han X; Barletta F; Lucas J; Subramanyam C; O'Donnell CJ; Tumey LN; Sapra P; Gerber HP; Ma D; Graziani EI
Bioconjug Chem; 2016 Aug; 27(8):1880-8. PubMed ID: 27412791
[TBL] [Abstract][Full Text] [Related]
45. Modulating Antibody-Drug Conjugate Payload Metabolism by Conjugation Site and Linker Modification.
Su D; Kozak KR; Sadowsky J; Yu SF; Fourie-O'Donohue A; Nelson C; Vandlen R; Ohri R; Liu L; Ng C; He J; Davis H; Lau J; Del Rosario G; Cosino E; Cruz-Chuh JD; Ma Y; Zhang D; Darwish M; Cai W; Chen C; Zhou H; Lu J; Liu Y; Kaur S; Xu K; Pillow TH
Bioconjug Chem; 2018 Apr; 29(4):1155-1167. PubMed ID: 29481745
[TBL] [Abstract][Full Text] [Related]
46. Application of a Biocatalytic Strategy for the Preparation of Tiancimycin-Based Antibody-Drug Conjugates Revealing Key Insights into Structure-Activity Relationships.
Steele AD; Kiefer AF; Hwang D; Yang D; Teijaro CN; Adhikari A; Rader C; Shen B
J Med Chem; 2023 Jan; 66(2):1562-1573. PubMed ID: 36599039
[TBL] [Abstract][Full Text] [Related]
47. A Patent Review on FDA-Approved Antibody-Drug Conjugates, Their Linkers and Drug Payloads.
Chia CSB
ChemMedChem; 2022 Jun; 17(11):e202200032. PubMed ID: 35384350
[TBL] [Abstract][Full Text] [Related]
48. Antibody conjugated nanoparticles as a novel form of antibody drug conjugate chemotherapy.
Johnston MC; Scott CJ
Drug Discov Today Technol; 2018 Dec; 30():63-69. PubMed ID: 30553522
[TBL] [Abstract][Full Text] [Related]
49. Improved Physical Stability of an Antibody-Drug Conjugate Using Host-Guest Chemistry.
Sonzini S; Greco ML; Cailleau T; Adams L; Masterson L; Vijayakrishnan B; Barry C; Howard P; Ravn P; van der Walle CF
Bioconjug Chem; 2020 Jan; 31(1):123-129. PubMed ID: 31794200
[TBL] [Abstract][Full Text] [Related]
50. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies.
Ducry L; Stump B
Bioconjug Chem; 2010 Jan; 21(1):5-13. PubMed ID: 19769391
[TBL] [Abstract][Full Text] [Related]
51. Structure-Activity Relationships of Bis-Intercalating Peptides and Their Application as Antibody-Drug Conjugate Payloads.
Petersen ME; Brant MG; Lasalle M; Fung VKC; Rojas AH; Wong J; Das S; Barnscher SD; Rich JR; Winters GC
J Med Chem; 2023 Jun; 66(12):8288-8309. PubMed ID: 37307297
[TBL] [Abstract][Full Text] [Related]
52. Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry.
McCombs JR; Owen SC
AAPS J; 2015 Mar; 17(2):339-51. PubMed ID: 25604608
[TBL] [Abstract][Full Text] [Related]
53. Enzymatic conjugation using branched linkers for constructing homogeneous antibody-drug conjugates with high potency.
Anami Y; Xiong W; Gui X; Deng M; Zhang CC; Zhang N; An Z; Tsuchikama K
Org Biomol Chem; 2017 Jul; 15(26):5635-5642. PubMed ID: 28649690
[TBL] [Abstract][Full Text] [Related]
54. Peptide-Drug Conjugate: A Novel Drug Design Approach.
Ma L; Wang C; He Z; Cheng B; Zheng L; Huang K
Curr Med Chem; 2017; 24(31):3373-3396. PubMed ID: 28393694
[TBL] [Abstract][Full Text] [Related]
55. An Update on the Synthesis of Pyrrolo[1,4]benzodiazepines.
Varvounis G
Molecules; 2016 Jan; 21(2):154. PubMed ID: 26828475
[TBL] [Abstract][Full Text] [Related]
56. A Brief Introduction to Antibody-Drug Conjugates for Toxicologic Pathologists.
Mecklenburg L
Toxicol Pathol; 2018 Oct; 46(7):746-752. PubMed ID: 30295169
[TBL] [Abstract][Full Text] [Related]
57. Synthesis and in vitro evaluation of SG3227, a pyrrolobenzodiazepine dimer antibody-drug conjugate payload based on sibiromycin.
Kemp GC; Tiberghien AC; Patel NV; D'Hooge F; Nilapwar SM; Adams LR; Corbett S; Williams DG; Hartley JA; Howard PW
Bioorg Med Chem Lett; 2017 Mar; 27(5):1154-1158. PubMed ID: 28188066
[TBL] [Abstract][Full Text] [Related]
58. Preclinical Characterization of Catabolic Pathways and Metabolism of ABBV-011, a Novel Calicheamicin-Based SEZ6-Targeting Antibody-Drug Conjugate.
Ladror D; Gu C; Tong V; Schammel A; Gavrilyuk J; Haight A; Sarvaiya H
Drug Metab Dispos; 2024 Jan; 52(2):135-142. PubMed ID: 38050039
[TBL] [Abstract][Full Text] [Related]
59. An Alternative Focus for Route Design for the Synthesis of Antibody-Drug Conjugate Payloads.
Tiberghien AC; Howard PW; Goundry WRF; McCormick M; Parker JS
J Org Chem; 2019 Apr; 84(8):4830-4836. PubMed ID: 30602115
[TBL] [Abstract][Full Text] [Related]
60. Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy.
Hartley JA
Expert Opin Biol Ther; 2021 Jul; 21(7):931-943. PubMed ID: 32543981
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
